Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat.
Bigham
Sarah
S
McGuigan
Christopher
C
MacDonald
Bridget K
BK
D000293:Adolescent; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D000927:Anticonvulsants / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004347:Drug Interactions; D016903:Drug Monitoring; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007783:Lactones / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077213:Lamotrigine; D009765:Obesity / Q000517:prevention & control; D000077403:Orlistat; D014227:Triazines / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use
D019440:Anti-Obesity Agents; D000927:Anticonvulsants; D007783:Lactones; D014227:Triazines; D000077403:Orlistat; D000077213:Lamotrigine